“Our studies are open for those that have exhausted standard of care, and we're showing improved responses, and the data is promising. So, I really hope that as we scale up and generate more data, we can actually move to newly diagnosed patients.” - Diana Azzam, PhD, Assistant Professor at Florida International University, Co-Founder at First Ascent Biomedical

Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Diana Azzam, as they discuss technological innovations in guiding individualized patient treatments.

Tune in today!

"It's amazing how many companies there are and how many opportunities for a kind of a match between a human that needs some help and a company that can help." - Craig Serra, Head of Clinical Research Scientific and Technical Engagement, Flatiron Health

Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Craig Serra, as they discuss improving and extending the life of every person with cancer and learning from those experiences.

Tune in today!

"I learned very early on that the stupidest cancer cell was cleverer than the cleverest oncologist." - Justin Stebbing, Editor-in-Chief of Oncogene, previously the UK's first NIHR Research Translational Professor of Oncology, Professor of Biomedical Sciences, Anglia Ruskin University, Cambridge.

Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Professor Justin Stebbing, as they discuss insights into oncology, knowledge sharing, and the virtuous circle of translational research.

Tune in today!

"Technologies have changed enormously in terms of how we can basically procure, preserve, and then interrogate a tumor specimen...like effectively in real time, like a living cancer specimen." - Dr. Keith Flaherty, Director of Clinical Research at Massachusetts General Hospital Cancer Center, Professor of Medicine at Harvard Medical School, and Associate Physician of Hematology and Oncology at Mass. General Hospital.

Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and Dr. Keith Flaherty, Director of Clinical Research at Massachusetts General Hospital Cancer Center, as they discuss insights into new therapeutic interventions for oncology patients.

Tune in today!

"Artificial Intelligence is a tool that really levels up and creates almost like an equity for everybody to participate and, when used effectively, to really accelerate medicine's development." - Dr. Ole Isacson, Professor of Neurology and Neuroscience, Harvard Medical School.

Welcome to the February episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and Dr. Ole Isacson, Professor of Neurology and Neuroscience at Harvard Medical School and Biorasi Scientific Advisory Board member, as they review the integration of AI into the world of neuroscience.

Tune in today!

"The history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." - Will Greene, Prader-Willi syndrome patient advocate and Healthcare Engagement Lead at Roche

Welcome to Biorasi's first Few & Far Between episode of 2024! Join host Chris O'Brien and guest Will Greene, Prader-Willi syndrome (PWS) patient advocate and Healthcare Engagement Lead at Roche, as they explore rare disease diagnoses and the importance of newborn screening as a public health tool.

Tune in today!

"Patients have already been exposed to these large language models (LLMs). Yes, they are aware of the risks, but they are also very aware of the benefits. And we need to engage the public in defining what those [AI] policies are." Isaac [Zak] Kohane, Professor and Chair, Department of Biomedical Informatics, Harvard Medical School

Buckle up for the latest Few & Far Between podcast! We're taking a tour of the current state of AI in healthcare and clinical research. Join host Chris O'Brien and guest Zak Kohane, Professor and Chair, Department of Biomedical Informatics, Harvard Medical School, as they spotlight the evolution of LLMs in the lives of physicians and patients.

"And what I was really surprised about was that everybody was doing data collection in a different way. And I kept thinking that, gosh, there's a lot of recreation of the wheel when advocacy groups have not necessarily ever run a research study. And so I kept thinking about what opportunities do we have across rare disease to really elevate and accelerate all of this work around data collection." - Charlene Son Rigby, CEO at Global Genes

Welcome to Biorasi's Few & Far Between podcast! Join host Chris O'Brien and guest Charlene Son Rigby, CEO at Global Genes, as they discuss how to build an infrastructure for a world where clinical data is ready to be shared with all those who need it.